Bedrijfsoverzicht
Amarin Corporation plc is a pharmaceutical entity dedicated to the commercialization and development of therapeutics designed for the treatment of cardiovascular diseases across the United States, Europe, and international markets. The company's primary product offering is VASCEPA, a prescription-only omega-3 fatty acid formulation utilized as an adjunct therapy. Operating within the Healthcare sector specifically under the industry classification of Drug Manufacturers - General, Amarin functions as a specialized player in the medical technology and pharmaceutical landscape. The company maintains a market capitalization of $301.24M with an annual revenue of $213.65M and employs a workforce of 80 individuals. These valuation and revenue metrics indicate that Amarin operates as a mid-cap entity with a revenue profile that is substantial yet reflects the capital-intensive nature of the pharmaceutical development stage. The scale of the operation, supported by a cash reserve of $302.59M, suggests a balance between current operational capabilities and the significant resources required for research, development, and commercial expansion in the cardiovascular disease sector.
Financiële gezondheid
The financial performance of Amarin Corporation plc for the trailing twelve months demonstrates a revenue of $213.65M, a net income of $-38,798,000, and an EBITDA of $-10,913,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses, including research and development costs, exceed gross profits, a common characteristic in the early-to-mid stages of pharmaceutical product commercialization. The company reports a free cash flow of $-25,504,500, indicating a net cash outflow that reflects the heavy investment in sustaining operations and developing its therapeutic portfolio without the offset of sufficient operational cash generation. In terms of profitability efficiency, the company reports a gross margin of 56.6%, which indicates a strong pricing power or cost advantage in its manufacturing of VASCEPA relative to the cost of goods sold. However, this is contrasted by an operating margin of -4.6% and a profit margin of -18.2%, which collectively signal that high overheads and R&D expenditures are currently eroding bottom-line profitability. The balance sheet shows a total cash position of $302.59M against a total debt load of $8.23M, resulting in a debt-to-equity ratio of 1.79. Despite the negative debt-to-equity figure often implying leverage, the massive cash reserve relative to minimal debt suggests a highly conservative liquidity stance rather than a leveraged risk profile. Furthermore, the current ratio stands at 3.34, which indicates a robust short-term liquidity position where current assets significantly exceed current liabilities, ensuring the ability to meet short-term obligations. Return on Equity is recorded at -8.2% and Return on Assets at -1.3%, metrics that reveal that management is currently deploying capital to generate losses rather than profits, a typical scenario for growth-stage biopharmaceutical firms reinvesting heavily into future product pipelines.
Waarderingsbeoordeling
Valuation metrics for Amarin Corporation plc include a P/E Ratio (TTM) of N/A due to the lack of positive earnings, while the Forward P/E is listed at 12.38. The distinction between a non-existent trailing P/E and a specific forward P/E implies that the market prices the stock based on anticipated future earnings rather than current profitability, suggesting an expectation that earnings will turn positive in the coming period. The price-to-book ratio is 0.66, which indicates that the market values the company at a discount relative to its book value, a valuation often seen in biotech firms where intangible assets and future pipeline potential are not fully captured on the balance sheet. Alternative valuation measures such as a Price to Sales ratio of 1.41 and an EV/EBITDA of -525.10 provide context for the company's valuation in the absence of earnings; the negative EV/EBITDA confirms that the company is currently unprofitable on an earnings before interest, taxes, depreciation, and amortization basis. The 52-week price range spans from a low of $8.32 to a high of $20.90, establishing the volatility bounds within which the stock has traded over the past year. While the exact current trading price is not provided in the available facts, the valuation framework relies on these historical bounds to assess relative positioning within the healthcare sector. The beta value is 0.82, which indicates that the stock's price volatility is lower than the broader market benchmark, suggesting that AmRN tends to be less sensitive to general market swings than the average large-cap stock.
Growth & Income
The company's growth trajectory is characterized by a Revenue Growth (YoY) of -21.0%, while the Earnings Growth (YoY) is N/A due to negative earnings. The fact that revenue growth is negative implies a contraction in sales volume or pricing, while the absence of earnings growth data highlights the current inability to generate positive returns on capital. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company does not distribute cash to shareholders. Instead, the company reinvests its earnings, or rather its cash reserves, into growth initiatives such as clinical trials and market expansion rather than paying dividends to investors. The overall growth and income profile is defined by negative revenue growth and zero dividend payouts, reflecting a strategic focus on long-term product development and market penetration rather than immediate shareholder yield or short-term profitability. This profile aligns with the operational reality of a pharmaceutical company managing high burn rates to secure market position for its cardiovascular therapeutics.